INMUNE BIO INC. - COMMON STOCK

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

11 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

10 Jul 2023 16:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

24 May 2023 09:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

08 May 2023 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update

03 May 2023 16:10:51 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

24 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

19 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03

11 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

03 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

02 Mar 2023 16:05:52 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

21 Feb 2023 09:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

08 Feb 2023 08:45:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

25 Jan 2023 07:45:00 By Nasdaq GlobeNewswire

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

22 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

08 Dec 2022 08:00:02 By Nasdaq GlobeNewswire

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

06 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

29 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

14 Nov 2022 09:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

02 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

26 Oct 2022 08:10:00 By Nasdaq GlobeNewswire